Integrated Biology Platform
Delivering comprehensive solutions from early discovery through IND-enabling translational studies
PRECEDO Integrated Biology Platform
PRECEDO's Integrated Biology Platform integrates clinically relevant biological resources, diverse disease models, and validated assay systems. The platform supports small molecules, biologics, and targeted protein degraders across oncology, autoimmune, inflammatory, and metabolic disease areas — delivering comprehensive solutions from early discovery through IND-enabling translational studies.
Why chooses our services
• Multidisciplinary Expertise Across the Full Discovery Continuum
Our team integrates specialists in biochemistry, biophysics, cell biology, immunopharmacology, and in vivo pharmacology — enabling seamless cross-disciplinary study design from target characterization through patient-derived model evaluation.
• Clinical and Relevant Biological Resources at Scale
1,600+ PDOs, 800+ cancer cell lines, 400+ Ba/F3 lines, 150+ PDC models, and 480+ PDX models — continuously expanded, pathologically validated, and immediately deployable.
• End-to-End Platform: From Discovery to Patient-Derived Model
The platform spans protein production, mechanistic cellular pharmacology, primary immune cell assays, organoid-based screening, and in vivo efficacy — delivering data consistency across all study phases.
• Flexibility and Rapid Turnaround Aligned with Program Timelines
Flexible study design, rapid assay development, and scalable execution — from early exploratory screening to full IND-enabling packages — delivered in close collaboration with project teams without compromising data quality.
Reprogramming Cells, Empowering Medicine
©2026 PRECEDO Biotechnology Co., Ltd. Powered by：www.300.cn